AliveDx Submits 510(k) Notification for Innovative MosaiQ AiPlex® Vasculitis Test to the FDA AliveDx has announced the submission of a 510(k) premarket notification to the FDA for its MosaiQ AiPlex® Vasculitis test, aimed at enhancing autoimmune disease diagnostics.

AliveDx Submits 510(k) Notification for Innovative MosaiQ AiPlex® Vasculitis Test to the FDA #USA #AliveDx #MosaiQ #Eysins #Vasculitis

AliveDx Secures FDA Registration for MosaiQ® Multiplex Testing Instrument AliveDx has announced its MosaiQ® instrument is now registered as a Class II device with the FDA, enhancing diagnostic capabilities for autoimmune diseases and allergies in the US.

AliveDx Secures FDA Registration for MosaiQ® Multiplex Testing Instrument #USA #FDA_Approval #AliveDx #MosaiQ #Eysins

AliveDx Receives FDA Approval for MosaiQ Multiplex Testing Device Targeting Autoimmune Diseases and Allergies AliveDx's MosaiQ device has been granted Class II FDA approval, allowing multiplex testing for autoimmune diseases and allergies, revolutionizing patient diagnostics.

AliveDx Receives FDA Approval for MosaiQ Multiplex Testing Device Targeting Autoimmune Diseases and Allergies #USA #FDA_Approval #AliveDx #MosaiQ #Eysins

AliveDx Launches Innovative MosaiQ AiPlex Vasculitis Assay for Clinical Use in Europe AliveDx announces the successful launch of its MosaiQ AiPlex Vasculitis assay, which is now available for clinical utilization across Europe and CE-marking-approved nations.

AliveDx Launches Innovative MosaiQ AiPlex Vasculitis Assay for Clinical Use in Europe #Switzerland #AliveDx #MosaiQ #Eysins #Vasculitis

AliveDx Launches MosaiQ AiPlex® Vasculitis Assay for Clinical Use in Europe AliveDx has received IVDR-CE Mark approval for its MosaiQ AiPlex® Vasculitis assay, facilitating faster diagnosis of autoimmune vasculitis across Europe.

AliveDx Launches MosaiQ AiPlex® Vasculitis Assay for Clinical Use in Europe #Switzerland #AliveDx #MosaiQ #Eysins #Vasculitis

AliveDx Submits 510(k) Application for MosaiQ AiPlex® Multiplex Test for Systemic Connective Tissue Diseases AliveDx has submitted a 510(k) premarket notification to the FDA for its MosaiQ AiPlex® multiplex microarray aimed at diagnosing systemic connective tissue diseases efficiently.

AliveDx Submits 510(k) Application for MosaiQ AiPlex® Multiplex Test for Systemic Connective Tissue Diseases #AliveDx #MosaiQ #AiPlex

mein Durcheinander 🤦🤷‍♂️

#artwork #acrylicpainting #painting #art #artsky #blueart #bluepainting #blue #cool #abstract #abstractart #abstractpainting #contemporaryart #contemporarypainting #artist #expressionism #artforsale #kunst #artbluesky #artistonX #mosaiq #skecht #scrap

AliveDx Introduces Cutting-Edge MosaiQ AiPlex Multiplex Assay for Autoimmune Disease Diagnosis AliveDx proudly announces the IVDR-CE mark for its MosaiQ AiPlex CTDplus assay, enhancing diagnostic efficiency for autoimmune diseases.

AliveDx Introduces Cutting-Edge MosaiQ AiPlex Multiplex Assay for Autoimmune Disease Diagnosis #Switzerland #AliveDx #MosaiQ #Eysins #Autoimmune

AliveDx Launches Advanced MosaiQ AiPlex® CTDplus Test for Autoimmune Diseases AliveDx announces the IVDR-CE marking for its MosaiQ AiPlex® CTDplus multiplex test, enhancing the diagnosis of systemic autoimmune diseases and lab workflows.

AliveDx Launches Advanced MosaiQ AiPlex® CTDplus Test for Autoimmune Diseases #Switzerland #AliveDx #MosaiQ #Eysins #AiPlex_CTDplus

AliveDx Introduces New IVDR-CE Certified Diagnostic Tool for Autoimmune Diseases AliveDx has launched the MosaiQ AiPlex CTDplus, an IVDR-CE certified multiplex assay aimed at enhancing the diagnosis of systemic autoimmune diseases and improving lab efficiency.

AliveDx Introduces New IVDR-CE Certified Diagnostic Tool for Autoimmune Diseases #Switzerland #AliveDx #MosaiQ #Eysins #Autoimmune

AliveDx Expands Product Range for Autoimmune Diseases with New Multiplex Test for Systemic Rheumatic Diseases AliveDx has introduced its IVDR-CE marked MosaiQ AiPlex® CTDplus multiplex test to diagnose systemic autoimmune rheumatic diseases efficiently.

AliveDx Expands Product Range for Autoimmune Diseases with New Multiplex Test for Systemic Rheumatic Diseases #Switzerland #AliveDx #MosaiQ #Eysins #AiPlex_CTDplus

AliveDx Launches Innovative Multiplex Assay to Enhance Autoimmune Diagnostics AliveDx's new MosaiQ AiPlex CTDplus assay receives IVDR-CE mark, streamlining diagnostics for autoimmune rheumatic diseases across laboratories.

AliveDx Launches Innovative Multiplex Assay to Enhance Autoimmune Diagnostics #Switzerland #Autoimmune_Diseases #AliveDx #MosaiQ #Eysins